ArriVent BioPharma (AVBP) vs SL Science (SLBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ArriVent BioPharma (AVBP) has outperformed SL Science (SLBT) over the past year, losing 19.7% versus a loss of 85.3%. SL Science is the larger company by market cap ($852.4 million vs $823.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVBP | SLBT |
|---|---|---|
| Share price | $16.71 | $1.52 |
| Market cap | $823.93M | $852.35M |
| 1-day change | -1.07% | +0.66% |
| YTD return | -16.95% | -85.59% |
| 1-year return | -19.74% | -85.32% |
| EPS (TTM) | $-3.62 | $-0.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.83 | $14.50 |
| 52-week low | $11.36 | $1.42 |
| Distance from 52-week high | -53.36% | -89.52% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +82.53% | — |
| Average volume | 908.55K | 80.48K |
| Shares outstanding | 49.31M | 560.76M |
| Employees | 77 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVBP has outperformed SLBT by 65.6 percentage points over the past year.
About ArriVent BioPharma
AVBP stock →ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 77 employees
About SL Science
SLBT stock →SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
AVBP vs SLBT FAQ
Which is bigger, ArriVent BioPharma or SL Science?
SL Science (SLBT) is larger, with a market capitalization of $852.35M compared with $823.93M for ArriVent BioPharma (AVBP).
Which stock has performed better over the past year, AVBP or SLBT?
AVBP returned -19.74% over the past 12 months, compared with -85.32% for SLBT (price return, excluding dividends). Past performance does not predict future results.
Are ArriVent BioPharma and SL Science in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for ArriVent BioPharma and Biotechnology: Biological Products (No Diagnostic Substances) for SL Science.